Data from the trial is also slated to be presented at the International Association for the Study of Lung Cancer’s 17th World Conference on Lung Cancer on December 7.
The St. Helier, N.J.-based company’s Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death.
Data from 42 patients in the 80-patient Stellar trial indicated that treatment with the Optune TTFields device and standard chemotherapy was tolerable and safe for patients, and showed improvements in the 12-month survival rate and progression free survival, compared to control patients receiving chemotherapy alone.
“The interim Stellar results are very encouraging. We are pleased that the first clinical results in mesothelioma will be presented at IASLC and look forward to sharing additional data in pancreatic and ovarian cancer at our R&D day in December,” chief science officer Dr. Eilon Kirson said in prepared remark
In July, NovoCure said it won FDA premarket approval for its 2nd-generation Optune system designed to treat glioblastoma patients.
The next-generation device is smaller, lighter and features a tumor treating field generator that is less than half the weight and size of the 1st-generation Optune system, NovoCure said.
The post Novocure touts Phase II data for tumor-treating fields in mesothelioma appeared first on MassDevice.
from MassDevice http://ift.tt/2f9g6Gl
Cap comentari:
Publica un comentari a l'entrada